Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials

Area of Science:

• Public Health
• Epidemiology
• Vaccinology

Background:

• Minority communities in the U.S. have experienced a disproportionately high burden of COVID-19 (coronavirus disease 2019) cases and mortality.
• Black Americans face more than double the COVID-19 mortality rates compared to white Americans.
• Existing federal guidelines advocate for minority inclusion in vaccine trials, yet current protocols lack representative sampling.

Purpose of the Study:

• To highlight the critical need for adequate inclusion of minority populations in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccine trials.
• To underscore the implications of minority inclusion for the equitable distribution of COVID-19 vaccines.

Main Methods:

• Analysis of publicly available SARS-CoV-2 vaccine trial protocols.
• Review of federal guidelines regarding minority participation in clinical trials.
• Examination of COVID-19 epidemiological data concerning racial and ethnic disparities.

Main Results:

• No publicly accessible SARS-CoV-2 vaccine trial protocols currently mandate representative sampling of minority groups.
• Despite federal recommendations, a gap exists between guidelines and actual trial design concerning minority inclusion.
• Disparities in infection and mortality rates underscore the urgency for targeted research and inclusive trials.

Conclusions:

• Representative sampling of minority communities in SARS-CoV-2 vaccine trials is essential for developing effective prevention strategies.
• Inclusion is paramount for ensuring the safety, efficacy, and equitable distribution of vaccines across all populations.
• Addressing underrepresentation in trials is a critical step towards mitigating health disparities exacerbated by the pandemic.